NZX Announcements
Announcements from Blis Technologies lodged on the NZX
You can view our page on the NZX and our latest NZD share price here.
Click here to go to the Blis information page where you will see the latest news and share price data. For interim and annual results releases and annual reports click here to go to our Annual and Half Year Reports page.
Quick links:
2021 → 2020 →2019 →2018 →2017 →2016 →2015 →2021 Announcements
- Challenging market conditions in US impact half year results
- 2021 Annual Shareholder Meeting Results
- ASM Presentation
- ASM Chair and CEO address
- Probi Investment and Partnership Briefing - Investor Call Transcription
- Investor call slide deck – Probi partnership
- Investor call regarding announcement of Probi investment in Blis
- Major growth partnership with leading global probiotics company Probi
- Notice of meeting
- Proxy form
- Virtual meeting guide
- 2021 Annual Shareholder Meeting and Director Nominations
- FY21 Annual Result Release
- Probiotic strain approvals in India
- Sales model revised in Australia
- Strategic emphasis on D2C e-commerce growth
- Launch of 3rd commercial probiotic strain: to promote healthy skin
- Business performance and year end guidance update
- Tmall flagship store launch
2020 Announcements
- Strong HY21 performance despite challenging market conditions
- Appointment of exclusive cross border eCommerce service provider for China
- Distribution partner appointed for Canadian market
- 2020 Annual Meeting of Shareholders results
- 2020 ASM Chair and CEO address
- 2020 ASM Presentation
- Recommendation on Directors Fee Pool
- NZX Release Report on Directors Fee Pool
- Notice of meeting
- Proxy form
- Virtual meeting online portal guide
- Independent director fee review
- Blis delivers sustained profitable growth
- FY20 Annual Result Release
- Frank Spiewack joins the Executive Leadership Team
- Upgraded FY20 guidance
- BLIS appoints Tony Balfour as a director
- Business update
- Upgraded revenue and earnings
- Q3 FY20 performance update
- New product launch UltraBLIS
2019 Announcements
- NZX Price enquiry – BLT response
- NZX Price enquiry
- BLIS ThroatGuard Australian Probiotic Product of the Year
- All Regions Experiencing Sales Growth
- BLT Market Update Business Performance
- BLT 2019 Marketing Awards
- 2019 Annual Shareholder Meeting Results
- ASM Presentations and Business Update
- 2019 Chair & CEO Address
- 2019 Chair & CEO Presentation
- BLT Precautionary response completed
- BLT Chemical Incident at Dunedin Site
- Notice of Meeting 2019
- Proxy Form 2019
- BLT Annual meeting and director nominations
- M18 Health Canada Approval
- M18 GRAS No Objection
- FY19 guidance 01-04-19
- Australia approval BLIS M18
- Expanded launch into Australian market
- Market update 3rd quarter result FY19
2018 Announcements
- 2019 Annual Shareholder Meeting Results
- NZX Release - Board announcement 28 Sept 2018
- NZX Release 07092018 - iNova
- NZX release 20180803 Appointment Barry Richardson
- 2018 AGM Results
- ASM2018_final
- Blis Technologies performance update
- Notice of Meeting 2018
- Shareholder Proxy 2018
- Change of Registered Office and Address
- Blis Technologies launch of products on US Amazon platform
- Request Director Nominations
- Blis Technologies Limited Market Update and Release of Annual Report
- NZX BLIS announces new board member MAY42018
- Blis Technologies achieves another international regulatory milestone
- Blis Technologies launch new flavour variant of popular HoneyBlis
- Callaghan Innovation Grant for Blis Technologies
- Blis Technologies appoints new agency partner for the Indian market
- Blis Technologies Update - 22 January 2018
2017 Announcements
- New distribution partner for NZ Pharmacy channel
- BLIS - Australian Regulatory Approval
- New Chief Financial Officer Appointment
- Blis Technologies Ltd- NZX Release - 27 October 2017
- CFO Resignation-NZX Release
- Independent Directors and Election of Chair
- 28072017 Blis AGM Results v2
- AGM presentation 280717 _final
- CEO Presentation 28072017
- Maspex BLIS K12
- Director Remuneration Report-NZX release
- Directors Fees - SESI Report
- Notice of Meeting-BLT
- Proxy Form Shareholders - BLT
- Request for Director Nominations 2017
- Market Update and Annual Report Release
- Blis Technologies Limited - Director Resignation
- Blis Technologies reports a maiden EBITDA surplus
- BLT – Independent director status
- Notice under clause 30, Schedule 4 of the Financial Markets Conduct Act 2013
- SSH Notice - Edinburgh Equity Limited and A P Offen
- SSH Notice - Minchun Qiu
- SSH Notice - Wen Wu
- Updated guidance
- New European study
2016 Announcements
- Amended - Ongoing Disclosure Notice Brian Watson
- Annual Meeting- Voting Results
- Blis Technologies Affirms Revenue Expectations
- Blis Technologies Gets Key ‘Letter of No Objection’ From US Food and Drug Administration for Ingredient BLIS K12
- Blis Technologies Limited - Half Year Result
- Blis Technologies Limited - Shareholder Update
- Blis Technologies Records 123% Increase in Revenues to $5.6m
- Blis Technologies Wins Two Awards in Deloitte Fast 50
- Director Independence
- Independent Research Report
- Notice of Annual Meeting
- NOTICE OF CHANGE IN ISSUED SECURITIES – ISSUE OF ORDINARY SHARES
- Request for Director Nominations
- Updated Guidance
2015 Announcements
- BLIS Technologies Chief Executive Announces Resignation
- Blis Technologies Delivers Solid Half Year Result
- BLIS Technologies Gathering Steam in Offshore Markets
- BLIS Technologies Limited - Voting Results
- Director Independence
- Ear Infections Reduced Through Use Of Blis K12 - Italian Clinical Study
- Health Canada - Approvals for BLIS K12® Probiotic
- New Chief Executive Appointment
- Preliminary Results for BLIS probiotic trial
- Record Sales and Revised Guidance
- Some Change To Guidance After Discoloured Product Discovery
To view PDF documents you may need to install Adobe Acrobat Reader. Available as a free download from the official Adobe website:
